SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]

AI-generated source summary

The analysis assesses XBI, an ETF holding several positive signals with a strong rising trend. The system ranks it as a strong buy candidate, a score of 7.3 as of August 15, 2025. Since August 12, 2025, the ETF has gained 4.33%, an average of 1.08% daily. Current analysis suggests a potential 10.29% increase in the next three months. Expected returns range from 4.25% to 11.87%. However, the 12-month analysis projects a potential decline of approximately 19.18%. A short term perspective shows a potential price range between 50.20 to 73.29. The latest daily update for XBI highlights, upgraded to a strong buy candidate after a recent increase. The recent day has risen by 1.24% which translates from 89.57 to 90.68. The ETF's 52 week high indicates 105.47. Positive signals included both short and long-term moving averages, as per volume analysis trading levels can find support at 87.51 and 86.44.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   16 Aug 2025, 03:15 UTC

   The analyst published the original source item.

2. First prediction resolved

   22 Sept 2025, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   22 Sept 2025, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:15 UTC

   Tahlil Plus began monitoring the extracted predictions.